Difference between revisions of "WBConfCall 2021.11.04-Agenda and Minutes"
Varnaboldi (talk | contribs) |
|||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 4: | Line 4: | ||
== Helpdesk == | == Helpdesk == | ||
| − | * https://github.com/WormBase/website/issues/8445 | + | * Server error at tools/gmap/run - https://github.com/WormBase/website/issues/8445 |
| + | * Ref section for sca-1 - https://github.com/WormBase/website/issues/8447 | ||
| + | ** Kimberly will review and clean up any erroneous gene-paper connections | ||
| + | * 'index of expressed TFs for all the different cells'; Wed Oct 27 | ||
| + | ** https://github.com/WormBase/website/issues/8448 | ||
== Varia == | == Varia == | ||
* Request from Bella Smith from Creative Biolabs, a life science company focusing on antibodies: "I am kindly writing to ask about getting Creative Biolabs listed and submitting C. elegans antibodies to your database." | * Request from Bella Smith from Creative Biolabs, a life science company focusing on antibodies: "I am kindly writing to ask about getting Creative Biolabs listed and submitting C. elegans antibodies to your database." | ||
** We don't curate commercial antibodies. We generate antibody records as we find them in the literature (lab generated). This means that, even if we were to accept a bulk submission from Creative Biolabs, there would be no Paper attached to the record. | ** We don't curate commercial antibodies. We generate antibody records as we find them in the literature (lab generated). This means that, even if we were to accept a bulk submission from Creative Biolabs, there would be no Paper attached to the record. | ||
| + | |||
| + | Should we make an exception for this company? Should we include antibodies from other companies? | ||
| + | |||
| + | Todd: we already provide commercial reagents in other sections. If the data is useful why shouldn't we distribute these data to our users? | ||
| + | |||
| + | Raymond: Since these are not published, we can't curate them and that't the main difference between commercial and non-commercial antibodies. We should be more restrictive on these commercial inputs. | ||
| + | |||
| + | Todd: Published doesn't mean true, so why not accepting commercial antibodies? We could have an additional section for commercial reagents on gene pages and this could be a great resource for users. | ||
| + | |||
| + | Daniela: We can reply asking for more details on the amount of data that they have and in the meanwhile ask our stakeholders if this is worth considering. | ||
| + | |||
| + | Valerio: Depending on what we decide, we could modify our automated extraction pipelines to identify commercial antibodies. | ||
| + | |||
| + | Karen: I don't see any downsides unless companies want to charge us for this service. Since other organisms are involved, this should also be discussed at the Alliance. | ||
Latest revision as of 15:59, 4 November 2021
Agenda and Minutes
Helpdesk
- Server error at tools/gmap/run - https://github.com/WormBase/website/issues/8445
- Ref section for sca-1 - https://github.com/WormBase/website/issues/8447
- Kimberly will review and clean up any erroneous gene-paper connections
- 'index of expressed TFs for all the different cells'; Wed Oct 27
Varia
- Request from Bella Smith from Creative Biolabs, a life science company focusing on antibodies: "I am kindly writing to ask about getting Creative Biolabs listed and submitting C. elegans antibodies to your database."
- We don't curate commercial antibodies. We generate antibody records as we find them in the literature (lab generated). This means that, even if we were to accept a bulk submission from Creative Biolabs, there would be no Paper attached to the record.
Should we make an exception for this company? Should we include antibodies from other companies?
Todd: we already provide commercial reagents in other sections. If the data is useful why shouldn't we distribute these data to our users?
Raymond: Since these are not published, we can't curate them and that't the main difference between commercial and non-commercial antibodies. We should be more restrictive on these commercial inputs.
Todd: Published doesn't mean true, so why not accepting commercial antibodies? We could have an additional section for commercial reagents on gene pages and this could be a great resource for users.
Daniela: We can reply asking for more details on the amount of data that they have and in the meanwhile ask our stakeholders if this is worth considering.
Valerio: Depending on what we decide, we could modify our automated extraction pipelines to identify commercial antibodies.
Karen: I don't see any downsides unless companies want to charge us for this service. Since other organisms are involved, this should also be discussed at the Alliance.
